BMS first to cross finish line in China PD-1 approval race

The State Drug Administration approved Opdivo nivolumab from Bristol-Myers Squibb Co. (NYSE:BMY), marking China’s first approval of an immuno-oncology agent,

Read the full 208 word article

User Sign In